Twitter with OTEurope

Article

It would probably be safe to assume that everyone reading this piece will have at least heard of Twitter; even if they are not actually using it. However, knowing that Twitter is out there and using it effectively are two very different things.

It would probably be safe to assume that everyone reading this piece will have at least heard of Twitter; even if they are not actually using it. However, knowing that Twitter is out there and using it effectively are two very different things.

www.twitter.com/oteurope will take you to Ophthalmology Times Europe's Twitter page and allows you to keep in touch with people and exchange information. Twitter is a microblogging platform that is increasingly being used as a business communication channel. It has different uses for different people but we think its value probably lies in a combination of broadcasting information and engaging in conversations with others.

It is a powerful medium to use for communicating with friends, colleagues and communities with shared interests. There are over three million registered users including ophthalmologists. We hope you find it useful and another method of keeping in touch with the ophthalmic community.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.